CEFPONIL-CV
Description
- Contains Cefpodoxime Proxetil 200 mg (cephalosporin) and Potassium Clavulanate 125 mg (β-lactamase inhibitor)
- Broad-spectrum action with enhanced efficacy against resistant bacteria
- Effective in treating respiratory, urinary, skin, and ENT infections
- Clavulanate prevents antibiotic degradation by β-lactamase-producing organisms
- Oral formulation ensures convenience and compliance
- Rapid symptom relief and reduced recurrence rates
- Suitable for adult and adolescent patients under medical supervision
Composition
CEFPODOXIME PROXETIL-200 MG, POTASSIUM CLAVULANATE-125 MG
Benefits
CEFPONIL-CV TAB provides broad-spectrum antibacterial action with enhanced resistance control, making it suitable for moderate to severe infections. It is particularly beneficial in treating bronchitis, sinusitis, pneumonia, tonsillitis, and urinary tract infections. The combination offers rapid symptom relief, fewer relapses, and a reduced risk of bacterial resistance. With excellent oral bioavailability and a well-tolerated profile, CEFPONIL-CV TAB is a trusted choice among healthcare professionals for safe and effective outpatient management of bacterial infections.
Introduction
CEFPONIL-CV TAB is a potent oral antibiotic formulation that combines Cefpodoxime Proxetil 200 mg, a third-generation cephalosporin, with Potassium Clavulanate 125 mg, a β-lactamase inhibitor. This synergistic combination enhances antibacterial efficacy by preventing resistance caused by β-lactamase-producing organisms. CEFPONIL-CV TAB is highly effective in the treatment of respiratory tract infections, urinary tract infections, skin infections, and ENT conditions caused by susceptible pathogens. The addition of Clavulanate ensures broader coverage and improved treatment outcomes, even in resistant bacterial infections.
